Evaluating MUTARS®
mega-endoprostheses 

Safety and effectiveness of the MUTARS® mega-endoprosthesis in patients with extensive bone defects: a multicenter observational cohort study

Background

At present, limb-sparing tumor resection is the mainstay of treatment for primary malignant bone tumors. Reconstruction of these commonly large bone defects are associated with frequent complications, including (aseptic) loosening, implant failure, and prosthetic joint infections. Aiming for a durable modular implant system, the Modular Universal Tumor And Revision System (MUTARS®) was introduced in 1991. Since then, the system has been used both in the reconstruction of tumor-related bone defects and increasingly in revision endoprosthesis of all major joints. However, compared with primary endoprosthesis, the total number of implanted modular endoprosthesis and their follow-up are limited. It is therefore particularly unfortunate that tumor or mega prostheses are not included in (international) implant registries. From an international collaborative initiative, we now aim to develop an international multicenter cohort study for these large endoprostheses specifically.


Aims

To perform a qualitative evaluation of MUTARS® endoprostheses survival, to describe failure types and mechanical and non-mechanical complications (according to the Henderson classification), and to describe risk factors for complications. At last, one of the aims is to evaluate the functional outcome of patients after being reconstructed with MUTARS® endoprostheses.

Project Outcomes


Team

Twitter
Email